Article

FDA grants clearance for myopia device

According to Oculus, its Myopia Master saves space and can be mounted on a workstation or an ophthalmic table. The software is operated directly via an inbuilt display.

The FDA has granted 510(k) clearance to a device (Myopia Master, Oculus) designed to combine the measurement methods axial length, refraction values and the central corneal radii.

Oculus has billed the device as the world’s first to combine the key measurement methods.

According to the company, the quick, contactless and extremely accurate measurement method for axial length is not influenced by the accommodation-status of the eye and delivers reproducible results. 

Thanks to the combination of measurements, the device is much more than just an auto-refractometer: the device opens up new possibilities for eye care professionals in providing the best care for their patients.

The device also saves space and can be mounted on a workstation or an ophthalmic table. The software is operated directly via the inbuilt display.

According to the American Academy of Ophthalmology, the number of Americans who are nearsighted has nearly doubled over the last 50 years to about 41.6 percent.

This is a trend that is seen around the world, but particularly in East and Southeast Asia, where 80 to 90 percent of children and young adults are myopic.

The Brien Holden Vision Institute in Australia estimates that around 50 percent of the world population will be affected by myopia by the year 2050. Moreover, a recent study by the European Eye Epidemiology Consortium shows that today 47 percent of Europeans between the ages of 25 and 29 are myopic.

Last year, the AAO formed the Myopia Task Force to b ring together experts in myopia from around the world to develop an action plan to delay the onset of myopia in children and slow the progression of the disease so the most devastating consequences of high myopia can be avoided.

Related Videos
(Image credit: Ophthalmology Times) World Cornea Congress IX: Epi-on and accelerated crosslinking with Kenneth Beckman, MD
(Image credit: Ophthalmology Times) The synergy of cornea, cataract, and refractive surgery through the decades: insights from George O. Waring IV, MD
(Image credit: Ophthalmology Times) AGS 2025: A look at Gemini and the MIGS revolution with Mona Kaleem, MD
(Image credit: Ophthalmology Times) AGS 2025: Development and evaluation of an AI model to set target IOP with Jithin Yohannan, MD, MPH
(Image credit: Ophthalmology Times) NeuroOp Guru: The role of muscle biopsy in heteroplasmy detection
(Image credit: Ophthalmology Times) AGS 2025: Achieving success as an academic ophthalmologist with Thomas V. Johnson III, MD, PhD
(Image credit: Ophthalmology Times) AGS 2025: Constance Okeke, MD, highlights 1-year Streamline canaloplasty outcomes
(Image credit: Ophthalmology Times) AGS 2025: Telemedicine and genetics for resource-efficient care with Louis R. Pasquale, MD
(Image credit: Ophthalmology Times) AGS 2025: Two-year data of bio-interventional cyclodialysis with scleral allograft with Leon W. Herndon Jr, MD
(Image credit: Ophthalmology Times) AGS 2025: Aqueous humor outflow improvement after excimer laser trabeculostomy with Clemens Strohmaier, PhD
© 2025 MJH Life Sciences

All rights reserved.